311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III

Early multi immune modulation with rilzabrutinib in patients with primary ITP after first line treatment failure A phase 3b study LUNA 4

Impact of helicobacter pylori infection on clinical outcomes in patients with immune thrombocytopenia A propensity matched analysis from a national cohort

First report A novel deep intronic mutation and treatment using hetrombopag olamine of a patient with MYH9 syndrome and immune thrombocytopenia

Dysregulation of the complement system in immune thrombocytopenia

Response to Hetrombopag Among patients with acute and persistent primary immune thrombocytopenia A real world study in China

Neonatal fc receptor antagonists in adult patients with primary immune thrombocytopenia Systematic review and meta analysis of randomized controlled trials

Effectiveness and safety of splenectomy or thrombopoietin receptor agonists as second line treatments for patients with immune thrombocytopenia in a real world setting

Retrospective analysis of efficacy and safety of romiplostim N01 in the treatment of chemotherapy induced thrombocytopenia CIT in solid tumors

Effectiveness of sirolimus for pediatric autoimmune cytopenias and factors associated with clinical response

Decoding acquired platelet dysfunction with eosinophilia Clinical triad and flow cytometric signatures

Efficacy and safety of romiplostim N01 in cancer treatment–induced thrombocytopenia Results from a phase II off label study in China

Efficacy and safety of hetrombopag a novel thrombopoietin receptor agonist in children and adolescents with immune thrombocytopenia Results from a randomized multicenter placebo controlled phase 3 trial